XenoLight RediJect COX-2 Probe

XenoLight RediJect COX-2 is a a novel fluorescent imaging probe for pre-clinical research that specifically detects the cyclooxygenase-2 (COX-2) biomarker noninvasively in vivo as well as in ex vivo tissue analysis applications. Caliper’s RediJect COX-2 probe provides the ability to non-invasively detect COX-2 in early-stage cancer cells, with a level of sensitivity and accuracy not attainable by conventional methods.

The RediJect COX-2 probe is very specific, with good signal to background ratios, in targeting tumors that only over express the COX-2 biomarker. Images shown in figure 1 show specific targeting to HT-29 (COX-2 positive) tumors and not targeting to HCT-116 (COX-2 negative) tumors. The specificity is also confirmed in vitro with Nuance Multispectral imaging system.

• Novel ready-to-use probe to monitor COX-2 in vivo non-invasively 
• Dispensed to image 5 animals (explorer kit) or 20 animals (standard kit) 
• Monitor COX-2 ex vivo in tissue samples using Caliper's Nuance Multispectral imaging systems 
• In vivo imaging quality, validated on IVIS and Nuance imaging systems 

XenoLight RediJect COX-2 Probe Explorer Kit (P/N 133316)

          


XenoLight RediJect COX-2 Probe Standard Kit (P/N 133314)

          

---

Reference:
Md. Jashim Uddin, Brenda C. Crews et al. (2010). "Selective Visualization of Cyclooxygenase-2 in Inflammation and Cancer by Targeted Fluorescent Imaging Agents". Cancer Res May 1, 2010 70; 3618

Label License:
RediJect COX-2 probe is sold under license from Vanderbilt University for research and laboratory use only. Requests for licenses for diagnostics or therapeutics use should be directed to contact Vanderbilt University, Office of Technology Transfer and Enterprise Development, Nashville, Tennessee

In vitro and In vivo specificity of RediJect COX-2 probe

Figure 1: A. In vitro binding specificity of RediJect COX-2 probe to Cox2 positive HT29 cells and no targeting to COX-2 negative HCT116 cells using Nuance FX multispectral imaging system. B. Nu/Nu mice were s.c. injected with 2x10⁶ of HCT116 (left flank) and HT29 (right flank) tumor cells. Most of tumors were approximately 100 mm³ at day 16, when mice were injected with either RediJect COX-2 Probe (i.p.) or control dye. Mice were imaged at 3, 6 and 24 hours after injection with IVIS Spectrum (Ex570, Em620). Images shown were taken at 3 hours. Cox2 positive HT29 tumor showed preferential binding by the probe whereas the Cox2 negative HCT116 showed very little binding. Quantification of fluorescence signal from the tumors showed a steady decrease of the fluorescence signal at the 6 and 24 hours post injection C. A 2-fold difference between the Cox2 positive HT29 and Cox2 negative HCT116 was observed in RediJect COX-2 injected mice at 3 and 6 hours.